Search Result

Results for "

BP1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Aminopeptidase (2) AMPK (4) Amyloid-β (1) Androgen Receptor (2) Apoptosis (9) ATM/ATR (3) Autophagy (3) Bacterial (2) c-Myc (2) Calcium Channel (8) Casein Kinase (1) CDK (2) Cholinesterase (ChE) (1) Cyclophilin (1) DNA/RNA Synthesis (7) Drug Derivative (1) DYRK (1) Enteropeptidase (2) ERK (2) FAK (2) Ferroptosis (1) Fluorescent Dye (1) Fungal (3) HDAC (1) Hedgehog (2) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) IGF-1R (1) Insulin Receptor (2) Integrin (2) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) MDM-2/p53 (3) mTOR (13) NF-κB (1) Notch (1) Opioid Receptor (2) Phosphatase (1) PI3K (1) Pim (2) PROTACs (2) PTEN (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) Small Interfering RNA (siRNA) (18) Sodium Channel (8) STAT (6) TGF-beta/Smad (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (43) Cardiovascular Disease (8) Infection (3) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (8)
Oligonucleotides:	Rat Pre-designed siRNA Sets (3) Mouse Pre-designed siRNA Sets (3) Human Pre-designed siRNA Sets (12) siRNAs (18)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141898

Biotin-4-aminophenol	Fluorescent Dye	Others
Biotin-4-aminophenol is a biotin-phenol analog. Biotin-4-aminophenol generates free radicals and conjugates to tyrosine residues in proteins more efficiently and selectively than the previously reported BP1 ^[1].

HY-B0280

Ranolazine 4 Publications Verification CVT 303; RS 43285-003	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-162288

FAZ-3532 4 Publications Verification	DNA/RNA Synthesis	Cancer
FAZ-3532 is a G3BP inhibitor (K_d = 0.54 μM) which binds to the NTF2L nsP3 binding pocket in G3BP1. FAZ-3532 disrupts the co-condensation of RNA, G3BP1, and caprin 1. FAZ-3532 inhibits G3BP-driven stress granule formation. FAZ-3532 can be studied as a powerful tool to probe the biology of stress granules and a promising interventions designed to modulate stress granule formation ^[1].

HY-100493

BP-1-102 Maximum Cited Publications 11 Publications Verification	STAT	Cancer
BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

HY-144873

AVJ16	Insulin Receptor Apoptosis	Cancer
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein *IGF2BP1* with a good affinity of K_d of 1.4μM. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation ^[1].

HY-162289

FAZ-3780 2 Publications Verification	DNA/RNA Synthesis	Neurological Disease Cancer
FAZ-3780 is an inhibitor that binds to the NTF2L domain of *G3BP1/2. FAZ-3780 binds to the NTF2L nsP3 of G3BP1 with high affinity, with a K_d* of 0.15 μM and a Pep-FRET IC₅₀ of 0.7 μM. FAZ-3780 targets the protein-protein interaction domain of G3BP1/2, and specifically inhibits the co-condensation of G3BP1, caprin 1 and RNA in vitro. FAZ-3780 inhibits stress granule formation and disassembles pre-formed stress granules. FAZ-3780 can be used in studies related to cancer and neurodegenerative diseases ^[1].

HY-17401

Ranolazine dihydrochloride 4 Publications Verification CVT 303 dihydrochloride; RS 43285	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (I_Na and I_Kr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-124447

BTYNB	IGF-1R c-Myc Apoptosis TGF-beta/Smad	Cancer
BTYNB is a structure-specific nucleic acid binder and *IGF2BP1* inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the *IGF2BP1-RNA* interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the *MYCN/IGF2BP1* loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma ^[1] .

HY-156110

IGF2BP1-IN-1	Insulin Receptor	Cancer
IGF2BP1-IN-1 (Compound A11) is a *IGF2BP1* inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a K_D value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC₅₀: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model ^[1].

HY-N1677

2,6-Dimethoxy-1,4-benzoquinone	Akt mTOR Bacterial Fungal AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, mTOR, *4E-BP1, and AMPK, and attenuates mTORC1* activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H₂O₂ generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness ^[1] .

HY-N6954

Garcinone C 2 Publications Verification	ATM/ATR STAT CDK Hedgehog	Inflammation/Immunology Cancer
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog* signaling pathway. Garcinone C is orally active ^[1] .

HY-156257

UNC9512 1 Publications Verification	DNA/RNA Synthesis	Cancer
UNC9512 is a selective *53BP1* inhibitor with an IC₅₀ of 0.46 μM, and a K_d values of 0.17 μM. UNC9512 binds *53BP1* and its tandem Tudor domain, disrupts histone H4 interaction, and inhibits *53BP1* activity. UNC9512 can be used as a probe for DNA damage repair and Gene editing ^[1] .

HY-170872

PT-129	PROTACs DNA/RNA Synthesis	Cancer
PT-129 is a *G3BP1/G3BP2* PROTAC degrader. PT-129 inhibits the formation of stress granules, disassembles pre-existing stress granules, disrupts stress granule-mediated ATF4 trafficking via migratory exocytosis, and suppresses cancer cell proliferation. PT-129 is applicable to the research of lung cancer and melanoma ^[1].

HY-W412264

Pim-1/2 kinase inhibitor 1	Pim	Cancer
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of *4E-BP1* and p27 ^Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer ^[1].

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) ^[1].

HY-115531

UNC-2170	DNA/RNA Synthesis	Cancer
UNC-2170 is a functionally active, fragment-like ligand for *53BP1* (IC₅₀=29 µM; K_d=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) ^[1].

HY-W348485

WRX606	mTOR	Cancer
WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC₅₀ = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC₅₀ = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent ^[1] .

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of *4E-BP1* in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma ^[1] .

HY-P10323A

T7 Peptide TFA Tumstatin (74-98), human TFA	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of *4E-BP1* in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma ^[1] .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and *4E-BP1* proteins, downregulates the expression of *HIF-1α* and NF-κB, and reduces the protein expression of Notch ligands Dll4 and *Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase* and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections ^[1] .

HY-156906

UNC3474	MDM-2/p53	Cancer
UNC3474 is a small molecule ligand, binding with *53BP1. UNC3474 binds the aromatic methyl-lysine binding cage of 53BP1 ^TT, with a dissociation constant (K_d*) of 1.0 ± 0.3 μM. UNC3474 inhibits the recruitment of 53BP1 to DSBs by stabilizing a pre-existing autoinhibited state of 53BP1 in cells ^[1].

HY-RS06619

IGF2BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IGF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IGF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IGF2BP1 Human Pre-designed siRNA Set A IGF2BP1 Human Pre-designed siRNA Set A

HY-RS05189

G3BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for G3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

G3BP1 Human Pre-designed siRNA Set A G3BP1 Human Pre-designed siRNA Set A

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma ^[1].

HY-124072

HL001	Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species (ROS)	Cancer
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating *G3BP1, inducing reactive oxygen species* and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis ^[1] .

HY-124348

DM-PIT-1 3,5-Dimethyl PIT-1	PI3K	Cancer
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor. DM-PIT-1 decreases he expression of P-Akt, P-GSK-3-β, P-p70S6K, P-S6, P-4E-BP1. DM-PIT-1 induces apoptosis and shows anticancer activity. DM-PIT-1 has the potential for the research of ovarian cancer ^[1] .

HY-115869

RMC-4529	mTOR	Cancer
RMC-4529 has an IC₅₀ value of 1.0 nM against p-4E-BP1-(T37/46) in mTOR kinase cellular assay.

HY-149292

SR-4133	Casein Kinase	Cancer
SR-4133 is a potent and highly *CK1ε* selective inhibitor with an IC₅₀ of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 ^[1].

HY-P2819

Phosphofructokinase 1 PFK1	Phosphatase	Metabolic Disease
Phosphofructokinase 1 (PFK1) is a major regulatory enzyme targeting glycolytic pathway. Phosphofructokinase 1 catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6BP) to regulate glycolytic flux. Phosphofructokinase 1 is promising for research of cancer metabolic reprogramming (e.g., hypoxia adaptation, oxidative stress resistance) and metabolic syndromes ^[1].

HY-125151

BP-1-108	STAT Apoptosis	Cancer
BP-1-108 is a selective inhibitor of STAT5 (K_i=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer ^[1].

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing *ERK1/2* activity, and reducing the phosphorylation levels of *mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand*. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease ^[1] .

HY-170873

G3BP1/2-Targeting ligand-1	Ligands for Target Protein for PROTAC DNA/RNA Synthesis	Cancer
G3BP1/2-Targeting ligand-1 is the ligand for *G3BP1/2* that can be used as target protein ligand for synthesis of G3BP1/2 PROTAC degrader PT-129 (HY-170872) ^[1].

HY-111370

mTOR inhibitor-2	mTOR	Cancer
mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC₅₀ of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates ^[1].

HY-118897

UNC-2170 maleate	DNA/RNA Synthesis	Cancer
UNC-2170 maleate is the maleate salt form of UNC-2170 (HY-115531). UNC-2170 maleate is a selective inhibitor for the methyl-lysine binding protein *53BP1, with IC₅₀* of 29 µM and K_d of 22 µM. UNC-2170 maleate shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) ^[1].

HY-17401S

Ranolazine-d8 dihydrochloride CVT 303-d8 dihydrochloride; RS 43285-d8	Calcium Channel Sodium Channel Autophagy	Cardiovascular Disease Cancer
Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-181960

BP1.3656B	Histamine Receptor	Neurological Disease
BP1.3656B is a selective, orally active, blood-brain barrier-permeable histamine H3 receptor (histamine H3 receptor) inverse agonist/antagonist, with a K_B value of 0.08 nM for antagonizing agonist-induced activity and an IC₅₀ value of 0.38 nM for directly inhibiting the basal activity of the receptor. BP1.3656B reduces alcohol consumption, alcohol-seeking behavior, alcohol self-administration, motivation to drink, alcohol relapse, alcohol-induced hyperlocomotion, and binge alcohol intake. BP1.3656B is applicable for the research of alcohol use disorder ^[1].

HY-B0280S1

Ranolazine-d8	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S2

Ranolazine-d3	Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5 CVT 303-d₅; RS 43285-003-d₅	Isotope-Labeled Compounds Sodium Channel Calcium Channel	Cardiovascular Disease Cancer
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-17401R

Ranolazine dihydrochloride (Standard) CVT 303 dihydrochloride (Standard); RS 43285 (Standard)	Calcium Channel Sodium Channel Autophagy Reference Standards	Cardiovascular Disease Cancer
Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride). This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-N6954R

Garcinone C (Standard)	Reference Standards ATM/ATR STAT CDK Hedgehog	Inflammation/Immunology Cancer
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog* signaling pathway. Garcinone C is orally active ^[1] .

HY-RS14842

TNKS1BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TNKS1BP1 Human Pre-designed siRNA Set A TNKS1BP1 Human Pre-designed siRNA Set A

HY-RS14915

TP53BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TP53BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TP53BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TP53BP1 Human Pre-designed siRNA Set A TP53BP1 Human Pre-designed siRNA Set A

HY-RS17909

G3bp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
G3bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G3bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

G3bp1 Mouse Pre-designed siRNA Set A G3bp1 Mouse Pre-designed siRNA Set A

HY-RS22048

Tax1bp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tax1bp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tax1bp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tax1bp1 Mouse Pre-designed siRNA Set A Tax1bp1 Mouse Pre-designed siRNA Set A

HY-RS08979

N4BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
N4BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for N4BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

N4BP1 Human Pre-designed siRNA Set A N4BP1 Human Pre-designed siRNA Set A

HY-RS12830

SH3BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SH3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SH3BP1 Human Pre-designed siRNA Set A SH3BP1 Human Pre-designed siRNA Set A

HY-RS14227

TAX1BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TAX1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAX1BP1 Human Pre-designed siRNA Set A TAX1BP1 Human Pre-designed siRNA Set A

HY-RS06904

IRF2BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IRF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IRF2BP1 Human Pre-designed siRNA Set A IRF2BP1 Human Pre-designed siRNA Set A

HY-RS08464

MIS18BP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MIS18BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MIS18BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MIS18BP1 Human Pre-designed siRNA Set A MIS18BP1 Human Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of *4E-BP1* in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma ^[1] .

HY-P10323A

T7 Peptide TFA Tumstatin (74-98), human TFA	Integrin FAK mTOR Apoptosis	Cancer
T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K_d of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of *4E-BP1* in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma ^[1] .

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma ^[1].

HY-P5118A

Tat-peptide 190-208 TFA	Peptides	Neurological Disease
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms ^[1].

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing *ERK1/2* activity, and reducing the phosphorylation levels of *mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand*. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease ^[1] .

HY-P5119

Tat-peptide control 168-189	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron ^[1].

HY-P5118

Tat-peptide 190-208	Peptides	Neurological Disease
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms ^[1].

HY-P11642

Sialorphin	ERK Androgen Receptor Opioid Receptor Enteropeptidase mTOR Aminopeptidase	Neurological Disease Inflammation/Immunology Cancer
Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing *ERK1/2* activity, and reducing the phosphorylation levels of *mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand*. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease ^[1] .

HY-P5119A

Tat-peptide control 168-189 TFA	Peptides	Neurological Disease
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1677

2,6-Dimethoxy-1,4-benzoquinone	Infection Quinones other families Classification of Application Fields Metabolic Disease Benzene Quinones Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Akt mTOR Bacterial Fungal AMPK
2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, mTOR, *4E-BP1, and AMPK, and attenuates mTORC1* activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H₂O₂ generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness ^[1] .

HY-N6954

Garcinone C 2 Publications Verification	other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Guttiferae Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	ATM/ATR STAT CDK Hedgehog
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog* signaling pathway. Garcinone C is orally active ^[1] .

HY-N11709

Theasaponin E1	Triterpenes Structural Classification Terpenoids Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and *4E-BP1* proteins, downregulates the expression of *HIF-1α* and NF-κB, and reduces the protein expression of Notch ligands Dll4 and *Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase* and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections ^[1] .

HY-N6954R

Garcinone C (Standard)	Structural Classification other families Xanthones Garcinia oblongifolia Champ. ex Benth. Guttiferae Phenols Polyphenols Plants Source Classification	Reference Standards ATM/ATR STAT CDK Hedgehog
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog* signaling pathway. Garcinone C is orally active ^[1] .

HY-N1677R

2,6-Dimethoxy-1,4-benzoquinone (Standard)	Quinones other families Benzene Quinones Plants Endogenous metabolite Source Classification	Reference Standards Akt mTOR Bacterial Fungal AMPK
2,6-Dimethoxy-1,4-benzoquinone (Standard) is the analytical standard of 2,6-Dimethoxy-1,4-benzoquinone (HY-N1677). This product is intended for research and analytical applications. 2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, mTOR, 4E-BP1, and AMPK, and attenuates mTORC1 activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H2O2 generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness.

HY-N15121

4-O-Methyl-ascochlorin	Structural Classification Monophenols Microorganisms Phenols Source Classification	Drug Derivative Apoptosis c-Myc AMPK mTOR
4-O-Methyl-ascochlorin (Compound MAC) is a derivative of Ascochlorin (HY-101021). 4-O-Methyl-ascochlorin can selectively induce apoptosis of K562 leukemia cells, cause G1 phase arrest and downregulate c-Myc expression. 4-O-Methyl-ascochlorin can promote the phosphorylation of AMPK and inhibit the phosphorylation of mTOR and its target proteins, including p70S6 K and 4E-BP-1. 4-O-Methyl-ascochlorin can be used for research of leukemia ^[1].

Species:	Human (9)
Tag:	His (6) Tag Free (2) Avi (1) GST (1) Fc (1)
Source:	HEK293 (3) Sf9 insect cells (2) E. coli (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P75560

	Aconitase 1/ACO1 Protein, Human (sf9, His) Cytoplasmic aconitate hydratase; Aconitase; IRP1; IRE-BP 1; ACO1; IREB1	Human	Sf9 insect cells
	The ACO1 protein is a bifunctional iron sensor that dynamically adapts to cellular iron levels. Under conditions of iron deficiency, it is converted to mRNA binding and regulates iron-related gene expression. Aconitase 1/ACO1 Protein, Human (sf9, His) is the recombinant human-derived Aconitase 1/ACO1 protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P702856

	G3BP1 Protein, Human (466a.a, His) G3BP-1; ATP-dependent DNA helicase VIII; hDH VIII; GAP SH3 domain-binding protein 1	Human	E. coli
	G3BP1 Protein, Human (His) is the recombinant human-derived G3BP1, expressed by E. coli , with N-6*His labeled tag.

HY-P704520

	*FGF-BP1* Protein, Human** 17 kDa heparin-binding growth factor-binding protein; FGFBP; FGF-BP; FGFBP1; FGF-BP1; FGFBP-1; FGFBPFGF-binding protein 1; fibroblast growth factor binding protein 1; fibroblast growth factor-binding protein 1; HBP17; HBP1717 kDa HBGF-binding protein; heparin-binding growth factor binding protein	Human	E. coli

HY-P77092

	*Syntaxin-BP1* Protein, Human (sf9, His-GST)** Syntaxin-binding protein 1; MUNC18-1; N-Sec1; UNC18A; p67	Human	Sf9 insect cells
	Syntaxin-BP1 protein critically regulates synaptic vesicle docking and fusion, binds GTP-binding proteins and ensures efficient neurotransmission. It interacts with syntaxin in a 1:1 ratio and shows specificity for syntaxin 1, 2, and 3 (excluding syntaxin 4). Syntaxin-BP1 Protein, Human (sf9, His-GST) is the recombinant human-derived Syntaxin-BP1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P71031

	Siglec-6 Protein, Human (HEK293, Fc) CD327; CD33 antigen-like 1; CD33L1; CDw327; OB-BP1; Siglec6; Siglec-6	Human	HEK293
	Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, Fc) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700825

	Siglec-6 Protein, Human (HEK293, His-Avi) CD327; CD33 antigen-like 1; CD33L1; CDw327; OB-BP1; Siglec-6; SIGLEC6; CD33L; OBBP1	Human	HEK293
	Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P77951

	CD42b/GP1BA Protein, Human (HEK293, His) GP-Ib alpha; GPIb-alpha; GPIbA; GP1BA; BDPLT1; BDPLT3; BSS; CD42B; CD42b-alpha; DBPLT3; GP1B; VWDP; BP1BA; MGC34595	Human	HEK293
	CD42b/GP1BA protein is an important platelet membrane protein that interacts with the A1 domain of von Willebrand factor and contributes to the formation of subendothelial platelet plugs. Its GP1BA subunit forms a disulfide-linked complex with two GP1BB subunits, collectively called GP-Ib. CD42b/GP1BA Protein, Human (HEK293, His) is the recombinant human-derived CD42b/GP1BA protein, expressed by HEK293 , with C-His labeled tag.

HY-P70415

	EIF4EBP1 Protein, Human (His) rHuEukaryotic translation initiation factor 4E-binding protein 1/EIF4EBP1, His; Eukaryotic Translation Initiation Factor 4E-Binding Protein 1; 4E-BP1; eIF4E-Binding Protein 1; Phosphorylated Heat- and Acid-Stable Protein Regulated by Insulin 1; PHAS-I; EIF4EBP1	Human	E. coli
	EIF4EBP1 is a translation initiation repressor protein that complexly regulates EIF4E activity. In the hypophosphorylated state, EIF4EBP1 competes with EIF4G1/EIF4G3 to inhibit translation by binding to EIF4E. EIF4EBP1 Protein, Human (His) is the recombinant human-derived EIF4EBP1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702529

	APPBP1-UBA3/NEDD8 E1 Protein, Human A-116A10.1; amyloid beta precursor protein binding protein 1; amyloid beta precursor protein binding protein 1, 59kDa; Amyloid beta precursor protein-binding protein 1, 59 kDa; amyloid beta precursor protein-binding protein 1, 59kD; Amyloid protein-binding protein 1; APPBP1APP-BP1; NEDD8 activating enzyme E1 subunit 1; NEDD8-activating enzyme E1 regulatory subunit; NEDD8-activating enzyme E1 subunit; protooncogene protein 1; Proto-oncogene protein 1; ula-1	Human	E. coli
	The APPBP1-UBA3/NEDD8 E1 protein is the regulatory subunit in the UBA3-NAE1 E1 enzyme complex and activates NEDD8 by adenylating its C-terminal glycine with ATP. This forms the NEDD8-UBA3 thioester, which is transferred to the catalytic cysteine of UBE2M. APPBP1-UBA3/NEDD8 E1 Protein, Human is a recombinant protein dimer complex containing human-derived APPBP1-UBA3/NEDD8 E1 protein, expressed by E. coli , with tag free. APPBP1-UBA3/NEDD8 E1 Protein, Human, has molecular weight of 60 kDa (APP-BP1) 50 kDa (UBA3).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

Host:	Mouse (21) Rabbit (26)
Reactivity:	Human (47) Mouse (27) Rat (24) Hamster (2)
Application:	IHC-P (34) ICC/IF (17) IF-Tissue (1) IP (16) WB (29) FC (10) ELISA (9)
Isotype:	IgG,Kappa (1) IgG (24) IgG1 (19) IgG/Kappa (1) IgG2a (1) IgG2b (1)
Conjugation:	Non-conjugated (47)
Clonality:	Monoclonal (30) Monoclonal Antibody (1) Recombinant (17)
Modification:	Phosphorylated (3) Unmodified (28)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82419

	AP-A Antibody (YA2164) AP-A; Aminopeptidase A; APA; BP1; CD249; EAP; Enpep; Gp160; Ly51	WB, IHC-P	Human
	AP-A Antibody (YA2164) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AP-A.

HY-P84548

	Phospho-eIF4EBP1 (Ser65) Antibody (YA4245) EIF4EBP1; BP-1; 4EBP1; 4E-BP1; PHAS-I	IHC-P, ICC/IF, FC, ELISA	Human
	Phospho-eIF4EBP1 (Ser65) Antibody (YA4245) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospho-eIF4EBP1 (Ser65).

HY-P84548A

	Phospho-eIF4EBP1 (Ser65) Antibody (YA4245)(PBS only) EIF4EBP1; BP-1; 4EBP1; 4E-BP1; PHAS-I	IHC-P, ICC/IF, FC, ELISA	Human
	Phospho-eIF4EBP1 (Ser65) Antibody (YA4245) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospho-eIF4EBP1 (Ser65).

HY-P82952

	DLX4 Antibody (YA2697) DLX4; BP1; DLX7; DLX8; DLX9; Homeobox protein DLX-4; Beta protein 1; Homeobox protein DLX-7; Homeobox protein DLX-8	WB, ICC/IF, IP	Human, Rat
	DLX4 Antibody (YA2697) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DLX4.

HY-P83061

	*CUG BP1* Antibody (YA2806)** CELF1; BRUNOL2; CUGBP; CUGBP1; NAB50; CUGBP Elav-like family member 1; CELF-1; 50 kDa nuclear polyadenylated RNA-binding protein; Bruno-like protein 2; CUG triplet repeat RNA-binding protein 1; CUG-BP1; CUG-BP- and ETR-3-like factor 1; Dead	WB, IHC-P, ICC/IF, FC, IP	Human, Mouse, Rat
	CUG BP1 Antibody (YA2806) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CUG BP1.

HY-P80552

	ATF2 Antibody (YA606) Activating transcription factor 2 antibody; Activating transcription factor 2 splice variant ATF2 var2 antibody; ATF 2 antibody; Atf-2 antibody; Atf2 antibody; ATF2 protein antibody; ATF2_HUMAN antibody; cAMP Response Element Binding Protein 2 antibody; cAMP response element binding protein CRE BP1 antibody; cAMP response element-binding protein CRE-BP1 antibody; cAMP responsive element binding protein 2, formerly antibody; cAMP-dependent transcription factor ATF-2 antibody; cAMP-responsive element-binding protein 2 antibody; CRE BP1 antibody; CRE-BP antibody; CREB 2 antibody; CREB-2 antibody; CREB2 antibody; CREBP1 antibody; Cyclic AMP dependent transcription factor ATF 2 antibody; Cyclic AMP-dependent transcription factor ATF-2 antibody; Cyclic AMP-responsive element-binding protein 2 antibody; D130078H02Rik antibody; D18875 antibody; HB 16 antibody; HB16 antibody; Histone acetyltransferase ATF2 antibody; MGC105211 antibody; MGC105222 antibody; MGC111558 antibody; MGC142504 antibody; mXBP antibody; MXBP protein antibody; Tg(Gzma-Klra1)7Wum antibody; TREB 7 antibody; TREB7 antibody	WB	Human, Mouse, Rat
	ATF2 Antibody (YA606) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATF2.

HY-P86907

	HUWE1 Antibody (YA6600) ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; HECT UBA and WWE domain containing protein 1 antibody; HectH9 antibody; Homologous to E6AP carboxyl terminus homologous protein 9 antibody; Huwe1 antibody; HUWE1_HUMAN antibody; Ib772 antibody; Large structure of UREB1 antibody; LASU1 antibody; Mcl 1 ubiquitin ligase E3 antibody; Mcl-1 ubiquitin ligase E3 antibody; Mule antibody; UBA and WWE domain-containing protein 1 antibody; Upstream regulatory element-binding protein 1 antibody; URE-B1 antibody; URE-binding protein 1 antibody; UREB1 antibody;	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	HUWE1 Antibody (YA6600) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HUWE1.

HY-P80552A

	ATF2 Antibody (YA606)(PBS only) Activating transcription factor 2 antibody; Activating transcription factor 2 splice variant ATF2 var2 antibody; ATF 2 antibody; Atf-2 antibody; Atf2 antibody; ATF2 protein antibody; ATF2_HUMAN antibody; cAMP Response Element Binding Protein 2 antibody; cAMP response element binding protein CRE BP1 antibody; cAMP response element-binding protein CRE-BP1 antibody; cAMP responsive element binding protein 2, formerly antibody; cAMP-dependent transcription factor ATF-2 antibody; cAMP-responsive element-binding protein 2 antibody; CRE BP1 antibody; CRE-BP antibody; CREB 2 antibody; CREB-2 antibody; CREB2 antibody; CREBP1 antibody; Cyclic AMP dependent transcription factor ATF 2 antibody; Cyclic AMP-dependent transcription factor ATF-2 antibody; Cyclic AMP-responsive element-binding protein 2 antibody; D130078H02Rik antibody; D18875 antibody; HB 16 antibody; HB16 antibody; Histone acetyltransferase ATF2 antibody; MGC105211 antibody; MGC105222 antibody; MGC111558 antibody; MGC142504 antibody; mXBP antibody; MXBP protein antibody; Tg(Gzma-Klra1)7Wum antibody; TREB 7 antibody; TREB7 antibody	WB	Human, Mouse, Rat
	ATF2 Antibody (YA606) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATF2.

HY-P84521

	53BP1 Antibody (YA4218) p202; 53BP1	IHC-P, FC, ELISA	Human
	53BP1 Antibody (YA4218) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to 53BP1.

HY-P89056

	XRCC6BP1 Antibody (YA8740) KUB3; XRCC6BP1	IHC-P	Human
	XRCC6BP1 Antibody (YA8740) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to XRCC6BP1.

HY-P84521A

	53BP1 Antibody (YA4218)(PBS only) p202; 53BP1	IHC-P, FC, ELISA	Human
	53BP1 Antibody (YA4218) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to 53BP1.

HY-P86435

	53BP1 Antibody (YA6127) TP53BP1; Tumor suppressor p53-binding protein 1; 53BP1; p53-binding protein 1; p53BP1	WB, ICC/IF, IP, ELISA	Human
	53BP1 Antibody (YA6127) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 53BP1.

HY-P89056A

	XRCC6BP1 Antibody (YA8740)(PBS only) KUB3; XRCC6BP1	IHC-P	Human
	XRCC6BP1 Antibody (YA8740) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to XRCC6BP1.

HY-P80001

	53BP1 Antibody (YA649) 1 Publications Verification	WB, ICC/IF, IHC-P, FC	Human, Mouse, Rat
	53BP1 Antibody (YA649) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 53BP1.

HY-P88300

	RBFOX1 Antibody (YA7984) 2BP1; A2BP1; FOX-1; FOX1; HRNBP1	IHC-P	Human, Mouse, Rat
	RBFOX1 Antibody (YA7984) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX1.

HY-P87861

	G3BP1 Antibody (YA7546)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	G3BP1 Antibody (YA7546) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to G3BP1.

HY-P88300A

	RBFOX1 Antibody (YA7984)(PBS only) 2BP1; A2BP1; FOX-1; FOX1; HRNBP1	IHC-P	Human, Mouse, Rat
	RBFOX1 Antibody (YA7984) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RBFOX1.

HY-P82503

	TAX1BP1 Antibody (YA2248) CALCOCO3; D6Ertd404e; D6Ertd772e; PRO0105; T6BP; TAX1BP1; tax1BP1b; TXBP151	WB, IHC-P	Human
	TAX1BP1 Antibody (YA2248) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TAX1BP1.

HY-P82503A

	TAX1BP1 Antibody (YA2248)(PBS only) CALCOCO3; D6Ertd404e; D6Ertd772e; PRO0105; T6BP; TAX1BP1; tax1BP1b; TXBP151	WB, IHC-P	Human
	TAX1BP1 Antibody (YA2248) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TAX1BP1.

HY-P88691

	SH3BP1 Antibody (YA8375) ARHGAP43	IHC-P	Human, Mouse
	SH3BP1 Antibody (YA8375) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SH3BP1.

HY-P83541

	N4BP1 Antibody (YA3286) C81621; AI481586	WB, IP	Human
	N4BP1 Antibody (YA3286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to N4BP1.

HY-P88611

	IRF2BP1 Antibody (YA8295) DKFZp434M154	IHC-P	Human, Mouse, Rat
	IRF2BP1 Antibody (YA8295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IRF2BP1.

HY-P88852

	GORAB Antibody (YA8536) GO; NTKLBP1; SCYL1BP1	ICC/IF, FC	Human
	GORAB Antibody (YA8536) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GORAB.

HY-P88691A

	SH3BP1 Antibody (YA8375)(PBS only) ARHGAP43	IHC-P	Human, Mouse
	SH3BP1 Antibody (YA8375) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SH3BP1.

HY-P83541A

	N4BP1 Antibody (YA3286)(PBS only) C81621; AI481586	WB, IP	Human
	N4BP1 Antibody (YA3286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to N4BP1.

HY-P88611A

	IRF2BP1 Antibody (YA8295)(PBS only) DKFZp434M154	IHC-P	Human, Mouse, Rat
	IRF2BP1 Antibody (YA8295) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IRF2BP1.

HY-P88852A

	GORAB Antibody (YA8536)(PBS only) GO; NTKLBP1; SCYL1BP1	ICC/IF, FC	Human
	GORAB Antibody (YA8536) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GORAB.

HY-P88256

	FGFBP1 Antibody (YA7940) FGF-BP; FGF-BP1; FGFBP; FGFBP-1; HBP17	IHC-P	Human
	FGFBP1 Antibody (YA7940) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FGFBP1.

HY-P82612

	CPEB1 Antibody (YA2357) CEBP; CPE-BP1; CPEB1; h CEBP; hCPEB 1	WB, IP	Human
	CPEB1 Antibody (YA2357) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CPEB1.

HY-P88256A

	FGFBP1 Antibody (YA7940)(PBS only) FGF-BP; FGF-BP1; FGFBP; FGFBP-1; HBP17	IHC-P	Human
	FGFBP1 Antibody (YA7940) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to FGFBP1.

HY-P82687

	G3BP Antibody (YA2432) G3BP1; G3BP; Ras GTPase-activating protein-binding protein 1; G3BP-1; ATP-dependent DNA helicase VIII; hDH VIII; GAP SH3 domain-binding protein 1	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	G3BP Antibody (YA2432) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to G3BP.

HY-P83105

	Aconitase 1 Antibody (YA2850) ACO1; IREB1; Cytoplasmic aconitate hydratase; Aconitase; Citrate hydro-lyase; Ferritin repressor protein; Iron regulatory protein 1; IRP1; Iron-responsive element-binding protein 1; IRE-BP 1	WB, ICC/IF	Human, Mouse, Rat
	Aconitase 1 Antibody (YA2850) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aconitase 1.

HY-P810679

	*Phospho-4E-BP1/2/3 (Thr45) Antibody (YA9937)* 4EBP3; 4E-BP3	WB, IHC-P, IP, ICC/IF, IF-Tissue	Human, Mouse, Rat
	Phospho-4E-BP1/2/3 (Thr45) Antibody (YA9937) is a Mouse-derived and non-conjugated IgG2a Monoclonal antibody, targeting to Phospho-4E-BP1/2/3 (Thr45).

HY-P89017

	ITGB1BP1 Antibody (YA8701) ICAP-1A; ICAP-1alpha; ICAP-1B; ICAP1; ICAP1A; ICAP1B	IHC-P	Human, Mouse, Rat
	ITGB1BP1 Antibody (YA8701) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ITGB1BP1.

HY-P89017A

	ITGB1BP1 Antibody (YA8701)(PBS only) ICAP-1A; ICAP-1alpha; ICAP-1B; ICAP1; ICAP1A; ICAP1B	IHC-P	Human, Mouse, Rat
	ITGB1BP1 Antibody (YA8701) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ITGB1BP1.

HY-P83326

	IGF2BP1 Antibody (YA3071) insulin-like growth factor 2 mRNA binding protein 1; IMP1; ZBP1; CRDBP; IMP-1; CRD-BP; VICKZ1	WB, IHC-P, IP	Human, Mouse
	IGF2BP1 Antibody (YA3071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP1.

HY-P83326A

	IGF2BP1 Antibody (YA3071)(PBS only) insulin-like growth factor 2 mRNA binding protein 1; IMP1; ZBP1; CRDBP; IMP-1; CRD-BP; VICKZ1	WB, IHC-P, IP	Human, Mouse
	IGF2BP1 Antibody (YA3071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF2BP1.

HY-P85851

	G3BP Antibody (YA5543) Ras GTPase-activating protein-binding protein 1; G3BP-1; EC 3.6.4.13; ATP-dependent DNA helicase VIII; hDH VIII; GAP SH3 domain-binding protein 1;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	G3BP Antibody (YA5543) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to G3BP.

HY-P80526

	eIF4EBP1 Antibody (YA650) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat, Hamster
	eIF4EBP1 Antibody (YA650) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to eIF4EBP1.

HY-P86332

	eIF4EBP1 Antibody (YA6024) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	eIF4EBP1 Antibody (YA6024) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to eIF4EBP1.

HY-P80786

	Phospho-eIF4EBP1 (Thr46) Antibody (YA230) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat
	Phospho-eIF4EBP1 (Thr46) Antibody (YA230) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-eIF4EBP1 (Thr46).

HY-P80526A

	eIF4EBP1 Antibody (YA650)(PBS only) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat, Hamster
	eIF4EBP1 Antibody (YA650) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to eIF4EBP1.

HY-P86088

	Phospho-eIF4EBP1(Thr37/46) Antibody (YA5780) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Phospho-eIF4EBP1(Thr37/46) Antibody (YA5780) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-eIF4EBP1(Thr37/46).

HY-P80786A

	Phospho-eIF4EBP1 (Thr46) Antibody (YA230)(PBS only) EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I	WB, IHC-P, IP	Human, Mouse, Rat
	Phospho-eIF4EBP1 (Thr46) Antibody (YA230) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-eIF4EBP1 (Thr46).

HY-P87018

	Palladin Antibody (YA6711) CGI 151 antibody; CGI151 antibody; KIAA0992 antibody; MYN antibody; Myoneurin antibody; pa antibody; Palladin cytoskeletal associated protein antibody; Palld antibody; PNCA1 antibody; Sarcoma antigen NY SAR 77 antibody; CGI 151 antibody; CGI151 antibody; KIAA0992 antibody; MYN antibody; Myoneurin antibody; pa antibody; Palladin cytoskeletal associated protein antibody; Palld antibody; PNCA1 antibody; Sarcoma antigen NY SAR 77 antibody; SIH002 antibody; Stx13BP1 antibody;	WB	Human
	Palladin Antibody (YA6711) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Palladin.

HY-P80438

	Beta Actin Antibody (YA823) 5+ Cited Publications A26C1A antibody; A26C1B antibody; ACTB antibody; ACTB_HUMAN antibody; Actin beta antibody; Actin cytoplasmic 1 antibody; Actin, cytoplasmic 1, N-terminally processed antibody; Actx antibody; b actin antibody; Beta cytoskeletal actin antibody; Beta-actin antibody; BRWS1 antibody; E430023M04Rik antibody; MGC128179 antibody; PS1TP5 binding protein 1 antibody; PS1TP5BP1 antibody; β-actin antibody	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Beta Actin Antibody is a non-conjugated and Mouse origined IgG1 monoclonal antibody, targeting to Beta Actin. It can be used as a loading control antibody.

HY-P87126

	TopBP1 Antibody (YA6819) DNA topoisomerase 2 binding protein 1 antibody; DNA topoisomerase 2-binding protein 1 antibody; DNA topoisomerase II binding protein 1 antibody; DNA topoisomerase II binding protein antibody; DNA topoisomerase II-beta-binding protein 1 antibody; DNA topoisomerase II-binding protein 1 antibody; DNA topoisomerase IIbeta binding protein 1 antibody; Hypothetical protein KIAA0259 [Fragment] antibody; KIAA0259 antibody; TOP2BP1 antibody; DNA topoisomerase 2 binding protein 1 antibody; DNA topoisomerase 2-binding protein 1 antibody; DNA topoisomerase II binding protein 1 antibody; DNA topoisomerase II binding protein antibody; DNA topoisomerase II-beta-binding protein 1 antibody; DNA topoisomerase II-binding protein 1 antibody; DNA topoisomerase IIbeta binding protein 1 antibody; Hypothetical protein KIAA0259 [Fragment] antibody; KIAA0259 antibody; TOP2BP1 antibody; TOPB1_HUMAN antibody; TOPBP 1 antibody; TopBP1 antibody; Topoisomerase (DNA) II binding protein 1 antibody; Topoisomerase II binding protein 1 antibody;	WB, IHC-P	Human
	TopBP1 Antibody (YA6819) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TopBP1.